Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody

Abhishek Seth; David Murray; Francis K. Buadi; Morie A. Gertz; Udit Yadav; Shaji K. Kumar; Wilson I. Gonsalves

doi:10.1111/ejh.14008

Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody

Abhishek Seth, David Murray, Francis K. Buadi, Morie A. Gertz, Udit Yadav, Shaji K. Kumar, Wilson I. Gonsalves

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Daratumumab is an anti-CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher-than-expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.

Original language	English (US)
Pages (from-to)	318-321
Number of pages	4
Journal	European Journal of Haematology
Volume	111
Issue number	2
DOIs	https://doi.org/10.1111/ejh.14008
State	Published - Aug 2023

Keywords

daratumumab
impaired mobilization
mass-spectrometry
multiple myeloma

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/ejh.14008

Cite this

@article{8ff37662ed6a439c9f4ea035da457257,

title = "Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody",

abstract = "Daratumumab is an anti-CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher-than-expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.",

keywords = "daratumumab, impaired mobilization, mass-spectrometry, multiple myeloma",

author = "Abhishek Seth and David Murray and Buadi, {Francis K.} and Gertz, {Morie A.} and Udit Yadav and Kumar, {Shaji K.} and Gonsalves, {Wilson I.}",

note = "Publisher Copyright: {\textcopyright} 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2023",

month = aug,

doi = "10.1111/ejh.14008",

language = "English (US)",

volume = "111",

pages = "318--321",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody

AU - Seth, Abhishek

AU - Murray, David

AU - Buadi, Francis K.

AU - Gertz, Morie A.

AU - Yadav, Udit

AU - Kumar, Shaji K.

AU - Gonsalves, Wilson I.

PY - 2023/8

Y1 - 2023/8

N2 - Daratumumab is an anti-CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher-than-expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.

AB - Daratumumab is an anti-CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher-than-expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.

KW - daratumumab

KW - impaired mobilization

KW - mass-spectrometry

KW - multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85159681664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159681664&partnerID=8YFLogxK

U2 - 10.1111/ejh.14008

DO - 10.1111/ejh.14008

M3 - Article

C2 - 37209032

AN - SCOPUS:85159681664

SN - 0902-4441

VL - 111

SP - 318

EP - 321

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 2

ER -

Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 monoclonal antibody

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this